Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast...
17 KB (1,479 words) - 16:30, 16 August 2024
8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration...
29 KB (2,696 words) - 14:16, 27 July 2024
Quinazoline (section Lapatinib)
drug lapatinib was approved by the U.S. FDA to treat advanced-stage or metastatic breast cancer in combination with Roche's capecitabine. Lapatinib eliminates...
14 KB (1,240 words) - 01:14, 27 July 2024
Lantidra Lantrisul Lantus (Sanofi-Aventis) lapaquistat acetate (USAN) lapatinib ditosylate (USAN) lapirium chloride (INN) laprafylline (INN) lapuleucel-T...
4 KB (278 words) - 08:25, 25 December 2023
while attempting to determine the toxicity and effectiveness of the drug. Lapatinib, FDA-approved for treatment in conjunction with chemotherapy or hormone...
10 KB (1,179 words) - 18:31, 8 August 2024
vulnerability to oxytosis/ferroptosis via a combination of siramesine and lapatinib. These cells also exhibited an autophagic cycle independent of ferroptotic...
24 KB (2,638 words) - 04:18, 19 August 2024
this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib...
20 KB (2,234 words) - 01:21, 22 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
68 KB (5,999 words) - 22:36, 15 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
31 KB (3,430 words) - 11:40, 29 July 2024
antibody margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose...
131 KB (14,807 words) - 00:05, 15 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
64 KB (7,427 words) - 21:08, 3 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
149 KB (15,717 words) - 06:34, 13 August 2024
to develop new therapeutic strategies. HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast...
18 KB (2,105 words) - 01:40, 20 August 2024
approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab...
43 KB (4,651 words) - 13:41, 27 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
24 KB (1,703 words) - 18:20, 18 August 2024
Clinical trials are in progress for other drugs such as everolimus, lapatinib and mifepristone. Common aspirin has been studied as a low-risk therapeutic...
59 KB (6,716 words) - 04:00, 16 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (579 words) - 06:46, 26 June 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (1,131 words) - 19:14, 31 March 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
15 KB (844 words) - 18:08, 21 March 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
5 KB (412 words) - 23:17, 19 June 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
17 KB (1,489 words) - 05:47, 7 April 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
92 KB (8,671 words) - 18:15, 17 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
34 KB (3,021 words) - 12:39, 5 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
13 KB (1,177 words) - 00:03, 12 August 2024
trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer.[clarification needed]...
67 KB (5,977 words) - 19:32, 17 August 2024
cells with acquired resistance to the HER2-inhibitors trastuzumab and/or lapatinib. This effect was increased when copanlisib was administered along with...
10 KB (789 words) - 19:58, 28 December 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
26 KB (2,420 words) - 06:06, 17 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
21 KB (1,649 words) - 23:02, 17 April 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
121 KB (13,799 words) - 20:57, 19 August 2024
proliferation and migration is diminished. Gefitinib, erlotinib, brigatinib and lapatinib (mixed EGFR and ERBB2 inhibitor) are examples of small molecule kinase...
60 KB (6,879 words) - 14:26, 16 July 2024